Pituitary Gland Carcinoma

However, a positive correlation between RSUME and HIF-1α expression was observed (p < 0.05). These results suggested that upregulated expression of RSUME may be involved in the formation and progression of renal cell carcinoma via interaction with VHL/HIF-1α signalling pathway, and thus RSUME may be a novel potential therapeutic target for renal cell carcinoma.

This review proposes an MRI-first, tiered imaging strategy and a pragmatic approach to tracer selection from the available armamentarium (&lsqb;11C]methionine, &lsqb;68 Ga]SSTR ligands, &lsqb;68 Ga]PentixaFor, &lsqb;18F]FET and &lsqb;18F]FDG). We emphasise how to optimise PET acquisition and reporting, and how to integrate imaging with endocrine phenotype, treatment history and surgical/radiosurgical planning to maximise clinical impact while safeguarding pituitary function.

SF3B1 somatic mutation status in lactotroph tumours-as assessed by digital PCR technology-is associated with a younger age at diagnosis and larger tumour diameter. However, in our cohort it does not appear to associate with histological features, higher recurrence, treatment resistance, tumour invasiveness, or long-term outcomes in our multi-centric cohort.

Sellar neurocytoma should be considered in the differential diagnosis of invasive sellar masses. Definitive diagnosis relies on immunohistochemical analysis demonstrating neuronal differentiation with low proliferative activity. Surgical management should prioritize maximal safe resection and optic decompression, avoiding aggressive cavernous sinus dissection. Adjuvant radiotherapy and long-term surveillance are essential when residual disease is present. https://thejns.org/doi/10.3171/CASE26205.

The endoscopic transsphenoidal approach has proven to be a safe and highly effective method for achieving GTR in patients with PPTs. Spindle cell oncocytoma, with a higher level of vascularization than PC and GCT, poses a greater risk of surgical complicationsand may result in non-GTR.

This case illustrates the rare presentation of a PIT-1 lineage adenoma secreting biologically active TSH, GH, and prolactin. Comprehensive hormonal evaluation and long-term biochemical and radiologic surveillance are essential, given the risk of incomplete remission despite apparent surgical cure.

This report describes a non-diabetic cat with HST secondary to a pituitary macroadenoma achieving sustained clinical and biochemical control with cabergoline monotherapy. This case demonstrates that a dopamine agonist might be an effective medical option in selected non-diabetic cats with HST, even in the presence of a large pituitary mass and signs of neurologic disease.

Although mice with Rb1 gene inactivation invariably develop pituitary adenomas, and some evidence suggests that a subset of pituitary adenomas have lack or reduced expression of Rb protein, to date no evidence has been reported that patients with germline mutations in the RB1 gene (that encodes for Rb protein) are at risk of developing pituitary adenomas. Here, we report the case of a patient with childhood (age 1 year) onset retinoblastoma because of a germline pathogenic variant of the RB1 gene who presented with a somatotropinoma diagnosed at a young age (20) and whose pituitary adenoma cells showed loss of expression of Rb protein by immunohistochemistry, suggesting a role of Rb in preventing the development of pituitary adenomas.

P2, N=10, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed

P=N/A, N=102, Not yet recruiting, Uludag University

On multivariate Cox regression, Type 2 (hazard ratio &lsqb;HR] = 2.76, 95% CI: 1.86-7.81, P = .009), and Type 3 (HR = 4.69, 95% CI: 1.65-13.3, P = .004) exhibited significantly higher mortality risk vs Type 1, independent of treatment modalities and presence of comorbidities. Applying a structural-functional acromegaly classification enables distinction of significant differences in long-term survival outcomes.

P1, N=50, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting